Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
EFFICACY AND SAFETY OF INCLISIRAN IN OUTPATIENTS WITH RECENT ACUTE CORONARY SYNDROME.
Anno:
2025
Background: Early and intensive low-density lipoprotein cholesterol (LDL-C) reduction after recent acute coronary syndrome (ACS) may reduce recurrent CV event risk. Aim: To evaluate the efficacy in LDL-C lowering added to usual care, of inclisiran administrated in outpatient with recent ACS. Methods: The routine data of 11 patients (8 M/3 F)…
Leggi di più
Anti-Inflammatory properties of Semaglutide: A Systematic Review and Meta-Analysis
Anno:
2025
Background: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has demonstrated efficacy in reducing the risk of adverse cardiovascular events in patients with type 2 diabetes mellitus (T2DM) who are at high cardiovascular risk or have established cardiovascular disease. Aim: This analysis aims to evaluate the anti-inflammatory effects of semaglutide…
Leggi di più
DETERMINANTS OF REDUCED 6-MINUTES WALKING DISTANCE AND ITS PROGNOSTIC VALUE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
Anno:
2025
Background: The six-minute walk test (6MWT) is a reliable measure of exercise capacity in patients suffering from cardiovascular diseases. While the prognostic significance of a reduced six-minute walk distance (6MWD) is well-established, there remains a paucity of comprehensive data on the factors that predict performance on this test. Purpose: To evaluate…
Leggi di più
The challenge of secondary cardiovascular prevention in very high Lipoprotein (a) level. A case report
Anno:
2025
Background While advances in technology and procedural techniques have significantly improved outcomes post-PCI, two pharmacological strategies have gained particular attention for their effectiveness in reducing long-term cardiovascular (CV) risk: antiplatelet therapies and lipid-lowering therapies (LLT). The 10-year recurrence risk for major CV events remains as high as 10–30%, due…
Leggi di più
EFFECT OF BEMPEDOIC ACID ADDED TO STANDARD HYPOLIPIDEMIC THERAPY ON LIPID TAGET ACHIEVEMENT AND VARIABILITY OF LDL-C VALUES IN HIGH RISK PATIENTS.
Anno:
2025
Background: Low-density lipoprotein cholesterol (LDL-C) variability could be related to increased cardiovascular risk in patients already treated with statins. Bempedoic acid (BA) is approved for the reduction of LDL-C in addition to or instead of statin therapy and ezetimibe.  Aim: to assess impact of BA addition to statin therapy…
Leggi di più
A NATIONAL PROJECT TO IMPROVE THE QUALITY OF SECONDARY PREVENTION STRATEGIES: THE RESULTS OF THE BRING-UP PREVENTION STUDY
Anno:
2025
Background. Adherence to guideline recommendations for secondary prevention strategies appears to be largely inadequate. Aim. To try to narrow the gap between what is recommended and what is implemented in clinical practice, we designed a national implementation science project, BRING-UP Prevention, based on educational programmes and patient data collection….
Leggi di più
Polypharmacy and acute kidney function impairment after starting bempedoic acid
Anno:
2025
Background. Bempedoic acid is an established treatment for dyslipidemia. In randomized clinical trial the treatment with bempedoic acid was associated with a small increase in creatinine levels. We present the  case of a patient with chronic coronary syndrome, heart failure with mild reduction of ejection fraction, and dyslipidemia with…
Leggi di più
CLINICAL IMPLEMENTATION O BEMPEDOIC ACID IN BLOOD LIPID MANAGEMENT: REAL-WORRLD DATA FROM AN ITALIAN LIPID CLINIC
Anno:
2025
Dyslipidemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD), and  lipid-lowering therapies (LLT) are critical for reducing morbidity and mortality. Despite the widespread use of statins (ST) and other LLT agents, a significant proportion of patents (Pts) fails to achieve target lipid levels due to inadequate response,…
Leggi di più
STATIN INTOLERANCE IN A REAL WORD SETTING OF ITALIAN CARDIOLOGY CENTERS: DATA FROM THE BRING-UP PREVENTION STUDY
Anno:
2025
Background. Statins are commonly prescribed to prevent cardiovascular disease by lowering low-density lipoprotein cholesterol (LDL-C). However, statin intolerance can limit their use or adherence to optimal high-intensity statin therapy. Observational studies have estimated intolerance in 25-30% of patients, while the prevalence in randomised clinical trials has been largely lower….
Leggi di più
TRIPLE ORAL COMBINATION TO LOWER LDL-C IN A PATIENT WITH POLYVASCULAR DISEASES
Anno:
2025
Patients with Peripheral Artery Disease are at increased risk of atherosclerotic cardiovascular (CV) events with high rate of recurrence. Bempedoic acid is a therapeutical option for the management of patients with hypercholesterolemia approved by EMA in 2020 and available in Italy since 2023.   We report the case of…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Cookie Policy Privacy Policy

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram